Original Paper

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models†

  1. Mallika Singh‡,§,
  2. Suzana S Couto§,
  3. William F Forrest,
  4. Anthony Lima,
  5. Jason H Cheng,
  6. Rafael Molina,
  7. Jason E Long,
  8. Patricia Hamilton,
  9. Angela McNutt,
  10. Ian Kasman,
  11. Michelle A Nannini,
  12. Hani Bou Reslan,
  13. Tim C Cao,
  14. Calvin CK Ho,
  15. Kai H Barck,
  16. Richard AD Carano,
  17. Oded Foreman,
  18. Jeffrey Eastham-Anderson,
  19. Adrian M Jubb,
  20. Napoleone Ferrara,
  21. Leisa Johnson*

Article first published online: 28 JUN 2012

DOI: 10.1002/path.4053

Issue

The Journal of Pathology

The Journal of Pathology

Volume 227, Issue 4, pages 417–430, August 2012

Additional Information

How to Cite

Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I., Nannini, M. A., Reslan, H. B., Cao, T. C., Ho, C. C., Barck, K. H., Carano, R. A., Foreman, O., Eastham-Anderson, J., Jubb, A. M., Ferrara, N. and Johnson, L. (2012), Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J. Pathol., 227: 417–430. doi: 10.1002/path.4053

Author Information

  1. Genentech Inc., 1 DNA Way, South San Francisco, CA, USA

  1. ‡

    Novartis Institutes for Biomedical Research, 4560 Horton Street, Emeryville, CA 94608, USA.

  1. §

    These authors contributed equally.

*Genentech Inc., 1 DNA Way, Room 12-322 (MS 37), South San Francisco, CA 94080, USA

  1. †

    Conflict of interest: all authors are/were employees of Genentech, a member of the Roche Group, and have/had financial holdings in Genentech/Roche during the course of this work. Genentech/Roche owns all patent rights.

  2. §

    These authors contributed equally.

Publication History

  1. Issue published online: 10 JUL 2012
  2. Article first published online: 28 JUN 2012
  3. Accepted manuscript online: 18 MAY 2012 09:17AM EST
  4. Manuscript Accepted: 10 MAY 2012
  5. Manuscript Revised: 5 MAY 2012
  6. Manuscript Received: 16 APR 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (8069K)
FilenameFormatSizeDescription
path_4053_sm_suppinfomate.doc87KSupporting Information: Supplementary materials and methods
path_4053_sm_suppinfofs1.pdf41587KSupporting Information: Figure S1. RIP-TβAg PNET model: generation, validation and analysis of anti-VEGF and sunitinib effects.
path_4053_sm_suppinfofs2.pdf41587KSupporting Information: Figure S2. Characterization and preclinical trials interrogating the effects of anti-VEGF on tumour burden, invasiveness and metastasis in the Rbfl/fl; p53frt/frt SCLC GEMM.
path_4053_sm_suppinfofs3.pdf41587KSupporting Information: Figure S3. Regression preclinical trials interrogating the effects of anti-VEGF on tumour burden, invasiveness and metastasis in the KrasLSL–G12D; p16/p19fl/fl; Pdx1-Cre PDAC GEMM.
path_4053_sm_suppinfofs4.pdf41586KSupporting Information: Figure S4. Preclinical trials in the regression setting interrogating the effects of anti-VEGF and sunitinib on tumour burden, invasiveness and metastasis in the KrasLSL–G12D; p53frt/frt NSCLC GEMM.
path_4053_sm_suppinfofs5.pdf41587KSupporting Information: Figure S5. Metastases in preclinical trials in the prevention setting in the KrasLSL–G12D; p16/p19fl/fl; Pdx1-Cre PDAC GEMM.
path_4053_sm_suppinfofs6.pdf41587KSupporting Information: Figure S6. Preclinical trials in the prevention setting interrogating the effects of anti-VEGF on tumour burden and invasiveness in the KrasLSL–G12D; p53frt/frt NSCLC GEMM.

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

View Full Article with Supporting Information (HTML) Get PDF (8069K)